soblidotin and Hematologic-Diseases
soblidotin has been researched along with Hematologic-Diseases* in 1 studies
Trials
1 trial(s) available for soblidotin and Hematologic-Diseases
Article | Year |
---|---|
Phase I study of TZT-1027, a novel synthetic dolastatin 10 derivative, for the treatment of patients with non-small cell lung cancer.
The purpose of this phase I study was to evaluate the maximum-tolerated dose (MTD), dose-limiting toxicity (DLT), the recommended dose for phase II study, pharmacokinetics, and antitumor activity of TZT-1,027 (soblidotin) in patients with non-small cell lung cancer (NSCLC) when administered every 3-4 weeks.. Eligible patients had the following characteristics: stage III/b or IV NSCLC that was refractory to conventional therapy or for which no standard therapy was available; Eastern Cooperative Oncology Group (ECOG) performance status (PS) Topics: Adult; Aged; Antineoplastic Agents; Area Under Curve; Carcinoma, Non-Small-Cell Lung; Dose-Response Relationship, Drug; Female; Half-Life; Hematologic Diseases; Humans; Injections, Intravenous; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Oligopeptides; Treatment Outcome | 2008 |